Olaf Witt

发表

Recurrent MET fusion genes represent a drug target in pediatric glioblastoma

Roland Eils, Thomas Zichner, Hans Lehrach, 2016, Nature Medicine.

Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions

Stefan M. Pfister, Damian Stichel, Andreas von Deimling, 2019, Acta Neuropathologica.

Histone Deacetylase 8 in Neuroblastoma Tumorigenesis

Barbara Hero, Annette Kopp-Schneider, Andreas von Deimling, 2009, Clinical Cancer Research.

The whole-genome landscape of medulloblastoma subtypes

Roland Eils, Steven J. M. Jones, Sebastian M. Waszak, 2017, Nature.

Dissecting the genomic complexity underlying medulloblastoma

Matthew J. Betts, Robert B. Russell, Roland Eils, 2012, Nature.

Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets

Stefan M. Pfister, Ivo Buchhalter, Benedikt Wiestler, 2016, Acta Neuropathologica.

Strategies to improve the quality of survival for childhood brain tumour survivors.

Stefan Rutkowski, Beate Timmermann, Andreas Wiener, 2015, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment

Stefan M. Pfister, Andrey Korshunov, Till Milde, 2012, Journal of Neuro-Oncology.

Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.

Roland Eils, Rainer König, Gary D Bader, 2014, Cancer cell.

Treatment of pediatric patients and young adults with particle therapy at the Heidelberg Ion Therapy Center (HIT): establishment of workflow and initial clinical data

Oliver Jäkel, Susanne Oertel, Jürgen Debus, 2012, Radiation oncology.

Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma

Roland Eils, Thomas Zichner, Hans Lehrach, 2013, Nature Genetics.

Implementation of mechanism of action biology-driven early drug development for children with cancer.

Gudrun Schleiermacher, Hubert Caron, Birgit Geoerger, 2016, European journal of cancer.

13-cis Retinoic Acid Treatment of a Patient With Chemotherapy Refractory Nephroblastomatosis

Jens-Peter Schenk, Andreas Kulozik, W. Behnisch, 2009, Journal of pediatric hematology/oncology.

Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin.

O. Witt, D. Reinhardt, A. Pekrun, 2003, Blood.

Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience

Martin Sill, Volker Hovestadt, Stefan M. Pfister, 2018, Acta Neuropathologica.

Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma.

Gary D Bader, Martin Sill, Axel Benner, 2011, Cancer cell.

Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes.

Roland Eils, Volker Hovestadt, Jan Koster, 2016, Cancer cell.

HDAC inhibitors: magic bullets, dirty drugs or just another targeted therapy.

O. Witt, Olaf Witt, R. Lindemann, 2009, Cancer letters.

INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies

Michael Platten, Annette Kopp-Schneider, Stefan M. Pfister, 2020, BMC Cancer.